Eleni Papachristodoulou, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 3 | 2024 | 2160 | 1.100 |
Why?
|
| Leukopenia | 1 | 2023 | 212 | 0.830 |
Why?
|
| Nephritis | 1 | 2023 | 149 | 0.800 |
Why?
|
| Pericarditis | 1 | 2023 | 135 | 0.770 |
Why?
|
| Polyarteritis Nodosa | 1 | 2021 | 70 | 0.740 |
Why?
|
| Tuberculosis, Spinal | 1 | 2019 | 16 | 0.700 |
Why?
|
| Spondylitis | 1 | 2019 | 20 | 0.700 |
Why?
|
| Myositis | 1 | 2023 | 269 | 0.690 |
Why?
|
| Brucellosis | 1 | 2019 | 21 | 0.690 |
Why?
|
| Immunity, Herd | 1 | 2020 | 46 | 0.690 |
Why?
|
| Granuloma | 1 | 2019 | 327 | 0.580 |
Why?
|
| Myocarditis | 1 | 2023 | 766 | 0.510 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3205 | 0.250 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
| Shock, Septic | 2 | 2019 | 760 | 0.200 |
Why?
|
| Quality of Life | 1 | 2023 | 13308 | 0.190 |
Why?
|
| Lupus Nephritis | 1 | 2024 | 318 | 0.180 |
Why?
|
| Interferons | 1 | 2024 | 705 | 0.180 |
Why?
|
| Fractures, Compression | 1 | 2021 | 129 | 0.170 |
Why?
|
| Measles virus | 1 | 2019 | 67 | 0.170 |
Why?
|
| Chondrocalcinosis | 1 | 2020 | 82 | 0.170 |
Why?
|
| Shiga Toxin | 1 | 2019 | 36 | 0.160 |
Why?
|
| Porphyrias | 1 | 2018 | 58 | 0.160 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2019 | 106 | 0.160 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 80 | 0.160 |
Why?
|
| Hepatitis | 1 | 2019 | 231 | 0.150 |
Why?
|
| Peroxidase | 1 | 2020 | 605 | 0.140 |
Why?
|
| Measles | 1 | 2019 | 185 | 0.140 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 225 | 0.140 |
Why?
|
| Heme | 1 | 2018 | 313 | 0.140 |
Why?
|
| Porphyrins | 1 | 2018 | 353 | 0.140 |
Why?
|
| Public Policy | 1 | 2021 | 560 | 0.140 |
Why?
|
| Mobility Limitation | 1 | 2019 | 402 | 0.130 |
Why?
|
| Bronchoscopy | 1 | 2021 | 911 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2021 | 702 | 0.120 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 664 | 0.110 |
Why?
|
| Gout | 1 | 2020 | 621 | 0.110 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 734 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 1529 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1792 | 0.100 |
Why?
|
| Pandemics | 3 | 2021 | 8623 | 0.100 |
Why?
|
| Cross Infection | 1 | 2021 | 1434 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2021 | 1601 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 6498 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4742 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1716 | 0.090 |
Why?
|
| Neutrophils | 1 | 2023 | 3767 | 0.090 |
Why?
|
| Cytokines | 1 | 2024 | 7344 | 0.080 |
Why?
|
| Humans | 15 | 2024 | 760613 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2019 | 5132 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3226 | 0.070 |
Why?
|
| Prevalence | 1 | 2023 | 15686 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 15840 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12968 | 0.060 |
Why?
|
| Depression | 1 | 2023 | 8045 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25941 | 0.050 |
Why?
|
| Cyprus | 1 | 2021 | 96 | 0.050 |
Why?
|
| Bronchoscopes | 1 | 2021 | 64 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2024 | 23374 | 0.050 |
Why?
|
| Calcium Pyrophosphate | 1 | 2020 | 53 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7408 | 0.050 |
Why?
|
| Equipment Contamination | 1 | 2021 | 179 | 0.040 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2019 | 26 | 0.040 |
Why?
|
| Colchicine | 1 | 2020 | 261 | 0.040 |
Why?
|
| Escherichia coli O157 | 1 | 2019 | 53 | 0.040 |
Why?
|
| Uroporphyrins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Porphyria, Erythropoietic | 1 | 2018 | 10 | 0.040 |
Why?
|
| Greece | 1 | 2019 | 336 | 0.040 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2018 | 11 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2018 | 165 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 40139 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2021 | 1809 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 523 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1575 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 80345 | 0.030 |
Why?
|
| Methotrexate | 1 | 2020 | 1718 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 1376 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 1949 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10343 | 0.030 |
Why?
|
| Animals | 1 | 2024 | 167960 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 1231 | 0.020 |
Why?
|
| Iron | 1 | 2018 | 1786 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 1758 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2021 | 2313 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 220359 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4167 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14661 | 0.010 |
Why?
|
| Female | 2 | 2019 | 391246 | 0.010 |
Why?
|
| Lung | 1 | 2019 | 9994 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29661 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 13262 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20509 | 0.010 |
Why?
|
| Adult | 2 | 2019 | 220007 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 64981 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 74333 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 169143 | 0.000 |
Why?
|
| Male | 1 | 2019 | 359718 | 0.000 |
Why?
|